Preview

Russian Journal of Pediatric Hematology and Oncology

Advanced search

Hematopoietic stem cell transplantation in patients with Hurler syndrome – myeloablative conditioning efficiency

https://doi.org/10.17650/2311-1267-2015-2-3-46-50

Abstract

Background. Allogenic hematopoietic stem cell transplantation (allo-HSCT) for patients with mucopolysaccharidosis is the radical method of therapy nowadays. Myeloablative conditioning regimens allow to achieve good engraftment and do not compromise clinical status of a patient.

Aim – to show effectiveness of allo-HSCT with myeloablative conditioning for patients with Hurler syndrome (HS).

Patients and methods. We analyzed 23 allo-HSCT at 22 patients with HS which were performed in 2002–2015. HSCT from unrelated donors (10/10 and 9/10) were performed in 18 cases. Transplant: bone marrow – 73.9 % (n = 17); peripheral blood stem cells – 17.4 % (n = 4); cord blood (CB) – 8.7 % (n = 2). Age median – 1.86 y.o. (10 months – 3.8 years). Conditioning regimen: Busulphan/Treosulphan + Fludarabine + Thiotepa/Melphalan and Antithymocyte Immunoglobulin +/– Rituximab (in case of HSCT from unrelated donor).

Results. 19 patients are alive now. 15 patients have complete donor’s chimerism now. All patients have good answer on general disease (best answer correlated with minimal interval between diagnosis and HSCT). Primary graft failure was in one case of CB transplantation. Graft rejection was diagnosed in 3 cases. Causes of death were infection complications in all cases. Results improved during last 5 years – good infection control and therapy of infection and immune complications. Median of follow-up is 48.62 (8–130) months, overall survival 83.2 %, event-free survival – 71.5 %.

Conclusion. Our results suggested that allo-HSCT with myeloablative conditioning (with Melphalan inclusion) for the patients with HS is effective way of therapy to stop neurodegeneration processes. Optimization of prevention and treatment of infection complications and graftversus-host disease allows to improve significantly results of HSCT.

About the Authors

K. I. Kirgizov
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation


E. A. Pristanskova
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


N. V. Sidorova
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


V. V. Konstantinova
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


B. B. Purbueva
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


O. S. Fink
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


O. L. Blagonravova
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


A. L. Pospelov
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


S. V. Mikhailova
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


A. A. Bologov
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


E. V. Skorobogatova
Russian Children's Clinical Hospital, Ministry of Health of Russia; 117 Leninskiy Prosp., Moscow, 117997, Russia
Russian Federation


References

1. Aldenhoven M., Boelens J.J., de Koning T.J. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 2008;14:485–98.

2. Guffon N., Souillet G., Maire I. et al. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998;133:119–25.

3. Bach G., Friedman R., Weissmann B., Neufeld E.F. The defect in the Hurler and Scheie syndromes: deficiency of alpha-Liduronidase. Proc Natl Acad Sci USA 1972;69:2048–51.

4. Russell C., Hendson G., Jevon G. et al. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 1998;53:349–61.

5. Polgreen L., Plog M., Tolar J. et al. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41:1005–11.

6. Fleming D.R., Henslee-Downey P.J., Ciocci G. et al. The use of partially HLAmismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I. Pediatr Transplant 1998;2:299–304.

7. Souillet G., Guffon N., Maire I. et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 2003;31:1105–17.

8. Orchard P.J., Milla C., Braunlin E. et al. Pre-transplant risk factors affecting outcome in Hurler syndrome. Bone Marrow Transplant 2010;45:1239–46.

9. Tolar J., Grewal S.S., Bjoraker K.J. et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant 2008;41:531–5.

10. Sauer M., Meissner B., Fuchs D. et al. Allogeneic blood SCT for children with Hurler's syndrome: results from the German multicenter approach MPS-HCT 2005. Bone Marrow Transplant 2009;43:375–81.

11. Grigull L., Beilken A., Schrappe M. et al. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler). Bone Marrow Transplant 2005;35:265–9.

12. Скоробогатова Е.В., Балашов Д.Н., Трахтман П.Е. и др. Итоги двадцатилетнего опыта трансплантации гемопоэтических стволовых клеток у детей. Педиатрия 2011;90(4):12–6. [Skorobogatova E.V., Balashov D.N., Trakhtman P.E. et al. Results of the 20-year experience of transplantation of hematopoietic stem cells of children. Pediatriya = Pediatrics 2011;90(4):12–6. (In Russ.)].

13. Peters C., Balthazor M., Shapiro E.G et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996;87:4894–902.

14. Handgretinger R., Klingebiel T., Lang P. et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001;27:777–83.

15. Polgreen L.E., Plog M., Schwender J.D. et al. Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:279–85.

16. Przepiorka D., Weisdorf D., Martin P. et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825–8.

17. Boelens J.J., Wynn R.F., O'Meara A. et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007;40:225–33.

18. Nguyen L., Fuller D., Lennon S. et al. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004;33:979–87.

19. Bearman S.I. Veno-occlusive disease of the liver. Curr Opin Oncol 2000;12:103–9.


Review

For citations:


Kirgizov K.I., Pristanskova E.A., Sidorova N.V., Konstantinova V.V., Purbueva B.B., Fink O.S., Blagonravova O.L., Pospelov A.L., Mikhailova S.V., Bologov A.A., Skorobogatova E.V. Hematopoietic stem cell transplantation in patients with Hurler syndrome – myeloablative conditioning efficiency. Russian Journal of Pediatric Hematology and Oncology. 2015;2(3):46-50. (In Russ.) https://doi.org/10.17650/2311-1267-2015-2-3-46-50

Views: 1315


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2311-1267 (Print)
ISSN 2413-5496 (Online)
X